Experiments were carried out in the skin of patients with leprosy to examine whether suppressor cell populations either exist in the skin of multibacillary lepromatous leprosy patients, can be activated with antigen, or are induced to emigrate into a cutaneous site from the circulation. For this purpose, purified protein derivative of tuberculin, a delayed-type antigen that generates a cell-mediated immune response, was introduced into the skin alone or with nonviable Mycobacterium leprae bacilli. Areas of induration and the resulting numbers and phenotypes of emigratory cells were not influenced by M. leprae and its products. Further studies examined the ability of M. leprae and its soluble products to modify the cutaneous response to intradermal injection of recombinant interleukin 2 (IL-2), a lymphokine that mimics a cell-mediated response. Neither the simultaneous injection of M. leprae and IL-2, nor the prior injection ofM. leprae followed in 2 days by IL-2, nor the prior aIministration of IL-2 followed in 4 days by M. leprae, into the same skin site, modified the zone of induration generated by IL-2. In addition, the immunocytochemical and histopathological evaluation of biopsy specimens of skin sites showed no difference between sites injected with IL-2 and sites injected with IL-2 and M. leprae. We conclude that suppressor T cells, if they exist, do not influence the gross or microscopic responsiveness of a cell-mediated skin reaction to antigen and IL-2. IL-2 did, however, enhance the responsiveness of skin-test-positive tuberculoid patients and family contacts to M. leprae antigens by a synergistic effect on the zone of induration and local cell accumulation.
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Patients with lepromatous leprosy fail to respond to Mycobacterium leprae antigens and do not generate a cellmediated immune reaction. This defect stems from the inability of T cells to undergo blastogenesis in the presence of specific M. leprae epitopes and to secrete important lymphokines such as interferon y and interleukin 2 (IL-2) (1-4). Although many authors have commented on the nature ofthis selective anergy, the underlying mechanism(s) is still unclear (5) . Based upon in vitro experiments, the presence of T cells that inhibit thymidine incorporation of lectin-stimulated peripheral blood T cells has been reported (6) (7) (8) . Such inhibitory cells were reported to be present in the blood of patients with lepromatous leprosy and absent from patients with the tuberculoid form of the disease and from normal individuals not infected with M. leprae. More recently, the isolation of T-cell clones with inhibitor activity was reported by Modlin et al. (9, 10) , who emphasized the possible suppressor role of such cells in leprosy.
However, the presence of specific suppressor T cells in lepromatous patients has not been proven. The activity expressed in culture systems that inhibits responses to lectins, bacillus Calmette-Guerin, and M. leprae is not specific for lepromatous patients and is also seen with cells from tuberculoid patients, normal individuals, and contacts (11) . In some cases it was clear that the products ofM. leprae were themselves nonspecifically suppressive in these in vitro systems (11, 12) . In addition, a role for monocyte/macrophage suppressor products induced by M. leprae has been suggested by many investigators (13) (14) (15) (16) .
We have therefore carried out in vivo experiments within the confines of leprosy lesions to explore the inhibitory properties of (i) preexisting cells of the infiltrate, (ii) particulate M. leprae and its soluble products, and (iii) newly emigrated blood cells in the presence or absence of exogenous antigens. We have quantitated suppression by virtue of the ability of these agents to modify the area of induration evoked by a reaction to the purified protein derivative of tuberculin (PPD) (17) or by the injection of recombinant IL-2, a lymphokine that mimics a cell-mediated immune reaction (18) . In other experiments either antigen or IL-2 was administered first and was followed 1-4 days later by the complementary antigens or IL-2 into the same site. Appropriate control sites for both antigens and IL-2 alone were injected nearby. All injection volumes were 100 ,ul.
MATERIALS AND METHODS
Local erythema and induration of the injected sites were evaluated daily. Selected sites of IL-2, antigen, and IL-2 plus antigen injection and matched control sites were biopsied (4-mm punch) 1-7 days after the first injection.
Histopathology. A part of each biopsy specimen was fixed in neutral buffered 10% formalin overnight, embedded in paraffin, sectioned, and stained with hematoxylin and eosin for histological diagnosis and acid-fast staining for enumeration of M. leprae.
Immunocytochemistry. Biopsy specimens were fixed in phosphate-buffered saline containing 3% paraformaldehyde, 75 mM lysine, and 10 mM sodium metaperiodate (20) and were processed as described (18) . Frozen sections were stained with mouse monoclonal antibodies as described (17) to identify cell types and phenotypes.
Monoclonal Antibodies. Mouse monoclonal antibodies were used for the identification of specific cell types. AntiLeu-4, anti-Leu-2a, and anti-Leu-3a (CD3, CD4, and CD8, anti-T cells) (21, 22) and anti-Leu-M5 (CD11c, anti-monocyte/macrophage) (23) were obtained from Becton Dickinson. OKT6 (24) (CD1, anti-Langerhans cells) was obtained from Ortho Diagnostics. Antibody 9.3F10 (anti-major histocompatibility complex class II antigen) was produced in this laboratory (25) .
RESULTS
The possible modulating influence of the lepromatous state and the administration ofM. leprae and its products was first examined in the presence of a delayed-type antigen-mediated event. For this purpose injection of PPD alone or in the presence of nonviable M. leprae was carried out. As noted previously, the response to PPD in sensitized human skin includes an emigratory event (17) , the generation of primary and secondary cytokines (26) , and complex responses of endothelium, fibroblasts, Langerhans cells, and keratinocytes (27, 28) .
Influence ofM. kprae Antigen on the Cutaneous Response to PPD. Fig. 1 with our former studies (17, 27) 
The nature and phenotype of emigratory cells were evaluated. Injection of PPD with or without M. leprae gave rise to the same increase in dermal cellularity, keratinocyte HLA-DR antigen expression, and dermal CD1+ cells. The majority of the emigratory T cells were of the CD4' phenotype and the dermal CD4+/CD8' T-cell ratios were similar in the presence or absence of M. leprae (Fig. 1C) .
We conclude that endogenous and/or newly administered exogenous M. leprae neither enhances nor suppresses the panoply of responses generated by the PPD antigens.
Responsiveness of Lepromatous and Tuberculoid Patients to IL-2. The initial study examined the basal reactivity of the skin of multibacillary and paucibacillary patients to the injection of IL-2. Lepromatous patients contain within their dermis heavily parasitized macrophages and a sparse T-cell infiltrate in which cells of the CD8' "suppressor/cytotoxic" phenotype predominate. In contrast, BT patients exhibit a more exuberant, cell-mediated, granulomatous reaction with few bacilli and many T cells, largely of the CD4' "helper" phenotype. The skin responses that resulted when IL-2 (10 ,ug) was introduced into these disparate milieus are shown in endogenous cellular infiltrate, number of bacilli, and expression of cell-mediated immunity failed to modify responsiveness to this lymphokine. Effect of Simultaneous Injection ofM. kprae and its Soluble Products on Responsiveness to IL-2. Lepromatous patients with a high B.I. (3+ or more), in various stages of treatment, were injected with 3-4 x 106 nonviable M. leprae bacilli. This quantity is routinely employed for evaluating skin reactivity in the Mitsuda reaction. Within 15 min after the deposition of baccilli, 10 ug of IL-2 was introduced into the same area, often via the same needle track. At the same time, but into different sites, control injections of leprosy bacilli or IL-2 alone were made. Zones of induration were measured over the next 7 days (Fig. 2B) . Both the maximum response at 24 hr and the rate of reduction in induration up to 7 days were not influenced by the presence of intact, extracellular M. leprae. None of the lepromatous patients responded to the bacilli during the 7-day period. The (Fig. 2D) . The prior injection of IL-2 did not lead to early cutaneous M. leprae responsiveness, nor did it modify the cutaneous responsiveness to a second injection of M. leprae. This is in keeping with in vitro studies in which IL-2 failed to enhance thymidine incorporation into lymphocytes from lepromatous leprosy patients either after addition in vitro (4) Fig. 3A shows that the prior injection of M. leprae had no influence on the cutaneous response to a subsequent injection of IL-2. The nature of the immediate response and the regression of induration were essentially similar in the IL-2-injected site and in the M. Ieprae-primed IL-2-injected site.
We conclude that during the 48 hr after the introduction of M. leprae into unresponsive lepromatous patients' skin, cells with the capacity to inhibit the dermal response to IL-2 were not observed.
Effect of M. keprae on the Response to IL-2 in AntigenReactive Individuals. To examine whether skin-test reactivity to M. leprae modulated IL-2 responsiveness, a similar experiment was carried out in skin of leprosy patients and family contacts who exhibited positive Fernandez and Mitsuda reactions. M. leprae (3-4 x 106 bacteria) was injected into two sites on the back of family contacts and examined at 24 and 48 hr. At this time IL-2 was injected directly into one of the M. leprae sites and at another, distant site. Zones of induration were evaluated over the next 48 hr (Fig. 3B) . Only small, but definite, zones of induration occurred at the sites injected with M. leprae alone. Injection of IL-2 alone gave the expected induration pattern noted previously. However, a significant enhancement in the extent of induration occurred when IL-2 was placed into a developing M. leprae reaction.
The simultaneous injection of soluble M. leprae antigens and IL-2 into the skin oftwo BT patients is depicted in Fig. 3C . IL-2 alone gave the expected induration pattern noted previously. Soluble antigens gave a typical Fernandez response, which persisted for up to 4 days and then subsided. A significant enhancement in the extent of induration was observed at 68 hr when the two mediators were injected into the same site.
These findings are consistent with the ability of IL-2 to enhance the cellular reactions occurring in response to an antigen-mediated event. Such experiments again failed to provide any evidence for the generation of an active suppressor cell population under these conditions.
Immunocytochemical The predominance of CD8' T cells in the infiltrates of lepromatous patients (CD4+/CD8' ratio of 0.9) was reversed in response to both IL-2 and IL-2 plus M. leprae. Forty-eight hours after injection, lepromatous patients showed CD4+/ CD8' T-cell ratios of 3.1 ± 0.6 and 2.2 ± 0.5 in response to IL-2 and IL-2 plus M. leprae, respectively. between their expression in the host and in the test tube. Those investigators who have considered the matter have reported only partial inhibition of thymidine incorporation with high effector cell ratios. This fact, when added to (i) a significant direct inhibitory role ofM. leprae macromolecules on monocyte-T-cell stimulation and (ii) a lack of specificity of the suppressor populations (11) , does not make a compelling case for T suppressor cells in the regulation ofthe disease process.
We have attempted to define an experimental situation that utilizes the location of bacillary replication. It employs the cutaneous infiltrate as it exists in the lepromatous patient and utilizes emigratory cell populations that are evoked either by antigen or by lymphokine. A number of parameters at both the gross and microscopic level serve to characterize the expression of cell-mediated immunity in the skin. Induration is a sensitive index of cell infiltration and has been used effectively in both murine and human systems to characterize cell-mediated reactions. It encompasses a variety of reactions including chemoattraction, endothelial cell transmigration, and the stimulation of the secretory repertoire of both macrophages and lymphocytes. Microscopically this is characterized by the presence of a predominant CD4' T-cell infiltrate, expression of interferon y-induced protein (IP-10), keratinocyte major histocompatibility complex class II determinants, Langerhans cell differentiation, and the production and function of cytotoxic effectors (17, 18, (26) (27) (28) (29) (30) .
We use this wide variety of immunological events to evaluate the possible suppressor role of T cells. For the first experiments we chose an antigen-driven event because it also incorporated a recognition phase and the clonal expansion of small T-cell populations. Subsequently we employed IL-2, a major growth factor for T cells whose presence is required for the expression of other lymphokines and cytokines. In both instances neither the cells involved in the lepromatous state nor those (0) migrating into cutaneous sites, (ii) activated by M. leprae antigen, or (iii), stimulated by crossreacting mycobacterial antigens (PPD) had a suppressive effect on the above parameters of cell-mediated immunity. We consider this strong evidence that suppressor T cells play no major role in down-regulating the essential features of cellular immunity in the skin of lepromatous patients.
It has recently come to our attention that the influence of M. leprae products on a tuberculin response had been investigated by Sengupta et al. (16) . Those authors mixed PPD and soluble molecules ofM. leprae prior to injection and reported a decided reduction in induration. Such data conflict with those reported here, and we suspect that mixing of these disparate molecules led to a reduction in tuberculin and leprosin activity.
An understanding of the T-cell unresponsiveness of lepromatous patients to M. leprae antigens is essential for a rational approach to any form of immunotherapy. Such mechanisms must consider findings in which LL/BL patients exhibit either a complete absence of in vivo T-cell reactivity or a spectrum of hyporesponsiveness (4) . The present data do not support a role for suppressor T-cell populations in explaining this anergy and point toward various defects in T-cell activation caused by ablation in the neonatal or postnatal period or defective antigen presentation. Numerous publications dealing with this subject in murine systems have implicated the thymus in the process. Exploration of the mechanisms of antigen presentation, T-cell receptor selectivity, and extent of T-cell deletions in patients with lepromatous leprosy promises to yield important information.
